Bristol, Pharmasset To Study Oral HCV Regimen Together
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.